Compromiso renal | 27 AGO 03

Nefropatía diabética

En los diabéticos es importante un abordaje intensivo y multidisciplinario para evitar el desarrollo y la progresión de la enfermedad renal y otras complicaciones diabéticas.
Autor: Dr. Rabkin R. Fuente: Department of Medicine, Division of Nephrology, Stanford University, Stanford, California, USA. Clin Cornerstone. 2003;5(2):1-11.

1. US Renal Data System. Excerpts from the United States Renal Data System 2001Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Am J Kidney Dis. 2001;38:S1-S248.
2. Molitch ME, DeFronzo RA, Franz MJ, et al. Diabetic nephropathy. Diabetes Care. 2003;26 (Suppl 1):S94-S98.
3. Parving HH. Diabetic nephropathy: Prevention and treatment. Kidney Int. 2001;60:2041-2055.
4. Mogensen CE, Schmitz O. The diabetic kidney: From hyperfiltration and microalbuminuria to end-stage renal failure. Med Clin North Am. 1988;72: 1465-1492.
5. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346:1145-1151.
6. Skyler JS. Microvascular complications. Retinopathy and nephropathy. Endocrinol Metab Clin North Am. 2001;30:833-856.
7. Ritz E, Tarng DC. Renal disease in type 2 diabetes. Nephrol Dial Transplant. 2001;16(Suppl 5):11-18.
8. Lane PH. Diabetic kidney disease: Impact of puberty. Am J Physiol Renal Physiol. 2002;283: F589-F600.
9. Nicholls AJ. The impact of atherosclerotic renovascular disease on diabetic renal failure. Diabet Med. 2002;19:889-894.
10. Mauer M, Fioretto P. Diabetic nephropathy as a model for the use of renal structural endpoints in clinical trials. Kidney Int Suppl. 1997;63: S155-S158.
11. Dalla Vestra M, Saller A, Bortoloso E, et al. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab. 2000;26(Suppl 4): 8-14.
12. Brenner BM. Remission of renal disease: Recounting the challenge, acquiring the goal. J Clin Invest. 2002;110:1753-1758.
13. Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes. 2001; 109(Suppl 2):S424-S437.
14. Jandeleit-Dahm K, Cooper ME. Hypertension and diabetes. Curr Opin Nephrol Hypertens. 2002;11: 221-228.
15. Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S80-S82.
16. Sowers JR. Update on the cardiometabolic syndrome. Clin Cornerstone. 2001;4:17-23.
17. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288:2579-2588.
18. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414: 813-820.
19. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med. 2002;251: 87-101.
20. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia. 2000;43: 1205-1223.
21. Rabkin R, Fervenza FC. Renal hypertrophy and kidney disease in diabetes. Diabetes Metab Rev. 1996;12:217-241.
22. Rincon-Choles H, Kasinath BS, Gorin Y, Abboud HE. Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl. 2002;82:8-11.
23. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med. 2001;345: 910-912.
24. Ruggenenti P, Remuzzi G. The role of protein traffic in the progression of renal diseases. Annu Rev Med. 2000;51:315-327.
25. Rippin JD, Patel A, Bain SC. Genetics of diabetic nephropathy. Best Pract Res Clin Endocrinol Metab. 2001;15:345-358.
26. Bakris GL. Microalbuminuria: What is it? Why is it important? What should be done about it? J Clin Hypertens (Greenwich). 2001;3:99-102.
27. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? Diabetes. 2000; 49:1399-1408.
28. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
29. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 2001;134:370-379.
30. Parving HH, Hovind P. Microalbuminuria in type 1 and type 2 diabetes mellitus: Evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep. 2002;4:387-393.
31. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345: 851-860.
32. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
33. Taal MW, Brenner BM. Combination ACEI and ARB therapy: Additional benefit in renoprotection? Curr Opin Nephrol Hypertens. 2002;11:377-381.
34. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
35. Orth SR, Viedt C, Ritz E. Adverse effects of smoking in the renal patient. Tohoku J Exp Med. 2001; 194:1-15.
36. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
37. Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care. 1998;21(Suppl 3): C35-C38.
38. Rabkin R, Simon NM, Steiner S, Colwell JA. Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med. 1970;282:182-187.
39. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: Incidence and risk factors. Am J Roentgenol. 1991;157:49-58.
40. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348: 383-393.


Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Contenidos relacionados
Los editores le recomiendan continuar con las siguientes lecturas:
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2018